Therapeutic efficacy of tazobactam/piperacillin in experimental urinary tract infections with β-lactamase-producing bacteria in mice

Abstract

The efficacy of tazobactam/piperacillin (TAZ/PIPC) in mice urinary tract infections with β-lactamase-producing bacteria were compared with those of piperacillin (PIPC) and sulbactam/cefoperazone (SBT/CPZ). TAZ/PIPC administration decreased the viable cell counts in kidney as effectively as SBT/CPZ, and their activities were superior to PIPC in infections with β-lactamase-producing Escherichia coli, Proteus vulgaris and Serratia marcescens. In mixed infection with β-lactamase-producing Staphylococcus aureus and PIPC-sensitive E. coli, concentration of PIPC following PIPC administration in kidney was lower than that following TAZ/PIPC administration. This result reflected the different efficacies of PIPC and TAZ/PIPC. From these results, it was suggested that TAZ/PIPC possessed as potent activity as SBT/CPZ against urinary tract infection, including polymicrobial infection.